PIK3CA mutation in non-metastatic triple-negative breast cancer as a potential biomarker of early relapse:A case report  

作　　者：Guillermo Arturo Valencia Patricia Rioja Zaida Morante Jhajaira M Araujo Heberth Daniel Vallejos Henry Guerra Henry L Gomez 

机构地区：[1]Department of Medical Oncology,Instituto Nacional de Enfermedades Neoplásicas,Lima 15000,Peru [2]Escuela de Medicina Humana,Universidad Privada San Juan Bautista,Lima 15067,Peru [3]Department of Medical Oncology,Russian Scientific Center of Radiology and Radiotherapy,Konkovo 117485,Moscow,Russia [4]Department of Pathology,Instituto Nacional de Enfermedades Neoplásicas,Lima 15000,Peru

出　　处：《World Journal of Clinical Oncology》2021年第8期702-711,共10页世界临床肿瘤学杂志（英文版）

摘　　要：BACKGROUND Currently,the detection of PIK3CA mutations is of special interest in personalized medicine because it is frequently found in triple-negative breast cancer(TNBC).The PI3KCA mutation is an independent negative prognostic factor for survival in metastatic breast cancer,and its prognostic value in liquid biopsy as a biomarker of treatment and early relapse is under investigation,both for metastatic disease and neoadjuvant scenario with curative intent.CASE SUMMARY A 54-year-old female patient with TNBC clinical stage IIIA,who,after receiving neoadjuvant chemotherapy(based on anthracyclines and taxanes),surgery,radiotherapy,and adjuvant capecitabine,was detected with a PI3KCA mutation in tissue and peripheral blood(ctDNA in liquid biopsy).After 10 mo,the patient had disease relapse of left cervical node disease.CONCLUSION The detection of PIK3CA mutation in TNBC after neoadjuvant treatment might be associated with early relapse or rapid disease progression.

关 键 词：Triple-negative breast cancer PIK3CA mutation Liquid biopsy Early relapse BIOMARKER Case report 

分 类 号：R737.9[医药卫生—肿瘤]